[1]
Liu B, Deng T, Zhang J. RISK FACTORS FOR CENTRAL SEROUS CHORIORETINOPATHY: A Systematic Review and Meta-Analysis. Retina (Philadelphia, Pa.). 2016 Jan:36(1):9-19. doi: 10.1097/IAE.0000000000000837. Epub
[PubMed PMID: 26710181]
Level 1 (high-level) evidence
[2]
Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. American journal of ophthalmology. 1967 Mar:63(3):Suppl:1-139
[PubMed PMID: 6019308]
[3]
Baran NV, Gürlü VP, Esgin H. Long-term macular function in eyes with central serous chorioretinopathy. Clinical & experimental ophthalmology. 2005 Aug:33(4):369-72
[PubMed PMID: 16033348]
[4]
Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology. 2010 Sep:117(9):1792-9. doi: 10.1016/j.ophtha.2010.01.023. Epub 2010 May 15
[PubMed PMID: 20472289]
[5]
Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: photodynamic therapy. American journal of ophthalmology. 2004 Jun:137(6):1073-80
[PubMed PMID: 15183792]
[6]
Arevalo JF, Espinoza JV. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2011 Aug:249(8):1159-66. doi: 10.1007/s00417-011-1651-7. Epub 2011 Mar 30
[PubMed PMID: 21448811]
Level 3 (low-level) evidence
[7]
Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Current eye research. 2010 Feb:35(2):91-8. doi: 10.3109/02713680903428306. Epub
[PubMed PMID: 20136418]
[8]
Lim JW, Kim MU. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2011 Jul:249(7):969-74. doi: 10.1007/s00417-010-1581-9. Epub 2010 Dec 8
[PubMed PMID: 21140161]
[9]
Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Transactions of the American Ophthalmological Society. 1986:84():799-845
[PubMed PMID: 3590481]
[10]
Iida T, Yannuzzi LA, Spaide RF, Borodoker N, Carvalho CA, Negrao S. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina (Philadelphia, Pa.). 2003 Feb:23(1):1-7; quiz 137-8
[PubMed PMID: 12652224]
[11]
Tittl MK, Spaide RF, Wong D, Pilotto E, Yannuzzi LA, Fisher YL, Freund B, Guyer DR, Slakter JS, Sorenson JA. Systemic findings associated with central serous chorioretinopathy. American journal of ophthalmology. 1999 Jul:128(1):63-8
[PubMed PMID: 10482095]
Level 3 (low-level) evidence
[12]
Carvalho-Recchia CA, Yannuzzi LA, Negrão S, Spaide RF, Freund KB, Rodriguez-Coleman H, Lenharo M, Iida T. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002 Oct:109(10):1834-7
[PubMed PMID: 12359603]
[13]
Karadimas P, Kapetanios A, Bouzas EA. Central serous chorioretinopathy after local application of glucocorticoids for skin disorders. Archives of ophthalmology (Chicago, Ill. : 1960). 2004 May:122(5):784-6
[PubMed PMID: 15136332]
[14]
Tsai DC, Chen SJ, Huang CC, Chou P, Chung CM, Chan WL, Huang PH, Lin SJ, Chen JW, Chen TJ, Leu HB. Risk of central serous chorioretinopathy in adults prescribed oral corticosteroids: a population-based study in Taiwan. Retina (Philadelphia, Pa.). 2014 Sep:34(9):1867-74. doi: 10.1097/IAE.0000000000000159. Epub
[PubMed PMID: 24743638]
[15]
Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Progress in retinal and eye research. 2015 Sep:48():82-118. doi: 10.1016/j.preteyeres.2015.05.003. Epub 2015 May 27
[PubMed PMID: 26026923]
[16]
Ulbig MR, Riordan-Eva P, Holz FG, Rees HC, Hamilton PA. Membranoproliferative glomerulonephritis type II associated with central serous retinopathy. American journal of ophthalmology. 1993 Oct 15:116(4):410-3
[PubMed PMID: 8213970]
[17]
Michael JC, Pak J, Pulido J, de Venecia G. Central serous chorioretinopathy associated with administration of sympathomimetic agents. American journal of ophthalmology. 2003 Jul:136(1):182-5
[PubMed PMID: 12834690]
[18]
Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S, Central Serous Chorioretinopathy Case-Control Study Group. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004 Feb:111(2):244-9
[PubMed PMID: 15019370]
Level 2 (mid-level) evidence
[19]
McCannel TA, Chmielowski B, Finn RS, Goldman J, Ribas A, Wainberg ZA, McCannel CA. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA ophthalmology. 2014 Aug:132(8):1005-9. doi: 10.1001/jamaophthalmol.2014.976. Epub
[PubMed PMID: 24852144]
[20]
Aliferis K,Petropoulos IK,Farpour B,Matter MA,Safran AB, Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors? Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 2012;
[PubMed PMID: 22156704]
[21]
Pierce KK, Lane RG. Central serous chorioretinopathy associated with the use of ephedra. Retinal cases & brief reports. 2009 Fall:3(4):376-8. doi: 10.1097/ICB.0b013e31818ad3ce. Epub
[PubMed PMID: 25389852]
Level 3 (low-level) evidence
[22]
Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. American journal of ophthalmology. 2010 Mar:149(3):361-363. doi: 10.1016/j.ajo.2009.11.017. Epub
[PubMed PMID: 20172062]
Level 3 (low-level) evidence
[23]
Tripathy K. Is Helicobacter pylori the culprit behind central serous chorioretinopathy? Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2016 Oct:254(10):2069-2070
[PubMed PMID: 27364118]
[24]
Mansuetta CC, Mason JO 3rd, Swanner J, Feist RM, White MF Jr, Thomley ML, McGwin G Jr, Emond TL. An association between central serous chorioretinopathy and gastroesophageal reflux disease. American journal of ophthalmology. 2004 Jun:137(6):1096-100
[PubMed PMID: 15183795]
[25]
Cotticelli L, Borrelli M, D'Alessio AC, Menzione M, Villani A, Piccolo G, Montella F, Iovene MR, Romano M. Central serous chorioretinopathy and Helicobacter pylori. European journal of ophthalmology. 2006 Mar-Apr:16(2):274-8
[PubMed PMID: 16703546]
[26]
Misiuk-Hojło M, Michałowska M, Turno-Krecicka A. Helicobacter pylori--a risk factor for the developement of the central serous chorioretinopathy. Klinika oczna. 2009:111(1-3):30-2
[PubMed PMID: 19517842]
[27]
Lin E, Arrigg PG, Kim RY. Familial central serous choroidopathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2000 Nov:238(11):930-1
[PubMed PMID: 11148819]
[28]
Oosterhuis JA. Familial central serous retinopathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 1996 May:234(5):337-41
[PubMed PMID: 8740256]
[29]
Park DW, Schatz H, Gaffney MM, McDonald HR, Johnson RN, Schaeffer D. Central serous chorioretinopathy in two families. European journal of ophthalmology. 1998 Jan-Mar:8(1):42-7
[PubMed PMID: 9590595]
[30]
Lehmann M, Bousquet E, Beydoun T, Behar-Cohen F. PACHYCHOROID: an inherited condition? Retina (Philadelphia, Pa.). 2015 Jan:35(1):10-6. doi: 10.1097/IAE.0000000000000287. Epub
[PubMed PMID: 25046398]
[31]
Gass JD. Central serous chorioretinopathy and white subretinal exudation during pregnancy. Archives of ophthalmology (Chicago, Ill. : 1960). 1991 May:109(5):677-81
[PubMed PMID: 2025170]
[32]
Cunningham ET Jr, Alfred PR, Irvine AR. Central serous chorioretinopathy in patients with systemic lupus erythematosus. Ophthalmology. 1996 Dec:103(12):2081-90
[PubMed PMID: 9003342]
[33]
Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta ophthalmologica. 2008 Mar:86(2):126-45
[PubMed PMID: 17662099]
[34]
Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology. 2008 Jan:115(1):169-73. doi: 10.1016/j.ophtha.2007.02.032. Epub
[PubMed PMID: 18166410]
[35]
Tsai DC, Chen SJ, Huang CC, Chou P, Chung CM, Huang PH, Lin SJ, Chen JW, Chen TJ, Leu HB, Chan WL. Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study. PloS one. 2013:8(6):e66858. doi: 10.1371/journal.pone.0066858. Epub 2013 Jun 24
[PubMed PMID: 23826160]
[36]
Gäckle HC, Lang GE, Freissler KA, Lang GK. [Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 1998 Aug:95(8):529-33
[PubMed PMID: 9782727]
[37]
Kim YT, Kang SW, Bai KH. Choroidal thickness in both eyes of patients with unilaterally active central serous chorioretinopathy. Eye (London, England). 2011 Dec:25(12):1635-40. doi: 10.1038/eye.2011.258. Epub 2011 Oct 21
[PubMed PMID: 22020172]
[38]
Prünte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. American journal of ophthalmology. 1996 Jan:121(1):26-34
[PubMed PMID: 8554078]
[39]
Okushiba U, Takeda M. [Study of choroidal vascular lesions in central serous chorioretinopathy using indocyanine green angiography]. Nippon Ganka Gakkai zasshi. 1997 Jan:101(1):74-82
[PubMed PMID: 9028111]
[40]
Spitznas M. Pathogenesis of central serous retinopathy: a new working hypothesis. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 1986:224(4):321-4
[PubMed PMID: 3710187]
[41]
Zhao M, Célérier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F, Behar-Cohen F. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. The Journal of clinical investigation. 2012 Jul:122(7):2672-9. doi: 10.1172/JCI61427. Epub 2012 Jun 11
[PubMed PMID: 22684104]
[42]
Jirarattanasopa P, Ooto S, Tsujikawa A, Yamashiro K, Hangai M, Hirata M, Matsumoto A, Yoshimura N. Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. Ophthalmology. 2012 Aug:119(8):1666-78. doi: 10.1016/j.ophtha.2012.02.021. Epub 2012 Apr 21
[PubMed PMID: 22521082]
[43]
Uyama M, Matsunaga H, Matsubara T, Fukushima I, Takahashi K, Nishimura T. Indocyanine green angiography and pathophysiology of multifocal posterior pigment epitheliopathy. Retina (Philadelphia, Pa.). 1999:19(1):12-21
[PubMed PMID: 10048368]
[44]
Yannuzzi LA,Slakter JS,Gross NE,Spaide RF,Costa D,Huang SJ,Klancnik JM Jr,Aizman A, Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina (Philadelphia, Pa.). 2003 Jun;
[PubMed PMID: 12824827]
Level 3 (low-level) evidence
[45]
Wang M, Sander B, la Cour M, Larsen M. Clinical characteristics of subretinal deposits in central serous chorioretinopathy. Acta ophthalmologica Scandinavica. 2005 Dec:83(6):691-6
[PubMed PMID: 16396646]
[46]
Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996 Dec:103(12):2070-9; discussion 2079-80
[PubMed PMID: 9003341]
[47]
Balaratnasingam C, Freund KB, Tan AM, Mrejen S, Hunyor AP, Keegan DJ, Dansingani KK, Dayani PN, Barbazetto IA, Sarraf D, Jampol LM, Yannuzzi LA. Bullous Variant of Central Serous Chorioretinopathy: Expansion of Phenotypic Features Using Multimethod Imaging. Ophthalmology. 2016 Jul:123(7):1541-52. doi: 10.1016/j.ophtha.2016.03.017. Epub 2016 Apr 12
[PubMed PMID: 27084564]
[48]
Imasawa M, Ohshiro T, Gotoh T, Imai M, Iijima H. Central serous chorioretinopathy following vitrectomy with intravitreal triamcinolone acetonide for diabetic macular oedema. Acta ophthalmologica Scandinavica. 2005 Feb:83(1):132-3
[PubMed PMID: 15715582]
[49]
Kim HC, Cho WB, Chung H. Morphologic changes in acute central serous chorioretinopathy using spectral domain optical coherence tomography. Korean journal of ophthalmology : KJO. 2012 Oct:26(5):347-54. doi: 10.3341/kjo.2012.26.5.347. Epub 2012 Sep 24
[PubMed PMID: 23060721]
[50]
Haimovici R, Gragoudas ES, Duker JS, Sjaarda RN, Eliott D. Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Ophthalmology. 1997 Oct:104(10):1653-60
[PubMed PMID: 9331207]
[51]
Kleinberger AJ, Patel C, Lieberman RM, Malkin BD. Bilateral central serous chorioretinopathy caused by intranasal corticosteroids: a case report and review of the literature. The Laryngoscope. 2011 Sep:121(9):2034-7. doi: 10.1002/lary.21967. Epub 2011 Aug 16
[PubMed PMID: 22024860]
Level 3 (low-level) evidence
[52]
Yang L, Jonas JB, Wei W. Optical coherence tomography-assisted enhanced depth imaging of central serous chorioretinopathy. Investigative ophthalmology & visual science. 2013 Jul 12:54(7):4659-65. doi: 10.1167/iovs.12-10991. Epub 2013 Jul 12
[PubMed PMID: 23737472]
[53]
Stattin M, Ahmed D, Forster J, Glittenberg C, Herrmann M, Krebs I, Ansari-Shahrezaei S. Detection of secondary choroidal neovascularization in chronic central serous chorioretinopathy by swept source-optical coherence tomography angiography. Acta ophthalmologica. 2019 Feb:97(1):e135-e136. doi: 10.1111/aos.13855. Epub 2018 Oct 3
[PubMed PMID: 30284407]
[54]
Wang MS, Sander B, Larsen M. Retinal atrophy in idiopathic central serous chorioretinopathy. American journal of ophthalmology. 2002 Jun:133(6):787-93
[PubMed PMID: 12036670]
[55]
Lim JW, Kang SW, Kim YT, Chung SE, Lee SW. Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy. The British journal of ophthalmology. 2011 Apr:95(4):514-7. doi: 10.1136/bjo.2010.182121. Epub 2010 Jul 19
[PubMed PMID: 20644214]
Level 2 (mid-level) evidence
[56]
Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. American journal of ophthalmology. 1983 Apr:95(4):457-66
[PubMed PMID: 6682293]
[57]
Gärtner J. Long-term follow-up of an ophthalmologist's central serous retinopathy, photocoagulated by sungazing. Documenta ophthalmologica. Advances in ophthalmology. 1987 May:66(1):19-33
[PubMed PMID: 3428072]
Level 3 (low-level) evidence
[58]
Sivaprasad S, Elagouz M, McHugh D, Shona O, Dorin G. Micropulsed diode laser therapy: evolution and clinical applications. Survey of ophthalmology. 2010 Nov-Dec:55(6):516-30. doi: 10.1016/j.survophthal.2010.02.005. Epub 2010 Sep 20
[PubMed PMID: 20850854]
Level 3 (low-level) evidence
[59]
Gupta B, Elagouz M, McHugh D, Chong V, Sivaprasad S. Micropulse diode laser photocoagulation for central serous chorio-retinopathy. Clinical & experimental ophthalmology. 2009 Nov:37(8):801-5. doi: 10.1111/j.1442-9071.2009.02157.x. Epub
[PubMed PMID: 19878226]
[60]
Chen SN, Hwang JF, Tseng LF, Lin CJ. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008 Dec:115(12):2229-34. doi: 10.1016/j.ophtha.2008.08.026. Epub
[PubMed PMID: 19041477]
[61]
Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. European journal of ophthalmology. 2008 Nov-Dec:18(6):934-40
[PubMed PMID: 18988165]
Level 3 (low-level) evidence
[62]
Verma L, Sinha R, Venkatesh P, Tewari HK. Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial [ISRCTN84128484]. BMC ophthalmology. 2004 Oct 29:4():15
[PubMed PMID: 15516262]
Level 2 (mid-level) evidence
[63]
Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008 Oct:115(10):1756-65. doi: 10.1016/j.ophtha.2008.04.014. Epub 2008 Jun 5
[PubMed PMID: 18538401]
Level 1 (high-level) evidence
[64]
Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehard U, Viestenz A, Naumann GO. Histopathological changes following photodynamic therapy in human eyes. Archives of ophthalmology (Chicago, Ill. : 1960). 2002 Jun:120(6):835-44
[PubMed PMID: 12049594]
[65]
Alcubierre R, Arias L, Lorenzo D, Pujol O, Rubio M. [Low-fluence photodynamic therapy in chronic central serous chorioretinopathy]. Archivos de la Sociedad Espanola de Oftalmologia. 2012 Jan:87(1):3-8. doi: 10.1016/j.oftal.2011.06.012. Epub 2011 Sep 14
[PubMed PMID: 22248651]
[66]
Butler AL, Fung AT, Merkur AB, Albiani DA, Forooghian F. Very minimal fluence photodynamic therapy for chronic central serous chorioretinopathy. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 2012 Feb:47(1):42-4. doi: 10.1016/j.jcjo.2011.12.020. Epub
[PubMed PMID: 22333850]
[67]
Witkin AJ, Brown GC. Update on nonsurgical therapy for diabetic macular edema. Current opinion in ophthalmology. 2011 May:22(3):185-9. doi: 10.1097/ICU.0b013e3283459724. Epub
[PubMed PMID: 21427573]
Level 3 (low-level) evidence
[68]
Chiang A, Regillo CD. Preferred therapies for neovascular age-related macular degeneration. Current opinion in ophthalmology. 2011 May:22(3):199-204. doi: 10.1097/ICU.0b013e32834597d9. Epub
[PubMed PMID: 21427571]
Level 3 (low-level) evidence
[69]
London NJ, Brown G. Update and review of central retinal vein occlusion. Current opinion in ophthalmology. 2011 May:22(3):159-65. doi: 10.1097/ICU.0b013e3283459737. Epub
[PubMed PMID: 21460724]
Level 3 (low-level) evidence
[70]
Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. American journal of ophthalmology. 2007 Jun:143(6):977-983
[PubMed PMID: 17459318]
[71]
Konstantinidis L, Mantel I, Zografos L, Ambresin A. Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy. European journal of ophthalmology. 2010 Sep-Oct:20(5):955-8
[PubMed PMID: 20306440]
[72]
Broadhead GK, Chang A. Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2015 Jun:253(6):979-81. doi: 10.1007/s00417-014-2891-0. Epub 2014 Dec 31
[PubMed PMID: 25547617]
[73]
Jampol LM, Weinreb R, Yannuzzi L. Involvement of corticosteroids and catecholamines in the pathogenesis of central serous chorioretinopathy: a rationale for new treatment strategies. Ophthalmology. 2002 Oct:109(10):1765-6
[PubMed PMID: 12359592]
[74]
Golshahi A, Klingmüller D, Holz FG, Eter N. Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study. Acta ophthalmologica. 2010 Aug:88(5):576-81. doi: 10.1111/j.1755-3768.2008.01467.x. Epub 2009 May 12
[PubMed PMID: 19456313]
Level 3 (low-level) evidence
[75]
Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina (Philadelphia, Pa.). 2011 Oct:31(9):1928-36. doi: 10.1097/IAE.0b013e31821c3ef6. Epub
[PubMed PMID: 21878843]
[76]
Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB. Finasteride for chronic central serous chorioretinopathy. Retina (Philadelphia, Pa.). 2011 Apr:31(4):766-71. doi: 10.1097/IAE.0b013e3181f04a35. Epub
[PubMed PMID: 21273946]
[77]
Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina (Philadelphia, Pa.). 2013 Nov-Dec:33(10):2096-102. doi: 10.1097/IAE.0b013e318297a07a. Epub
[PubMed PMID: 23719402]
Level 3 (low-level) evidence
[78]
Maier M, Stumpfe S, Feucht N, Strobl P, Rath V, Lohmann CP. [Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2014 Feb:111(2):173-80. doi: 10.1007/s00347-013-3001-0. Epub
[PubMed PMID: 24510173]
[79]
Breukink MB, den Hollander AI, Keunen JE, Boon CJ, Hoyng CB. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. Acta ophthalmologica. 2014 Sep:92(6):e488-90. doi: 10.1111/aos.12392. Epub 2014 Apr 2
[PubMed PMID: 24698599]
[80]
Gruszka A. Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report. European review for medical and pharmacological sciences. 2013 May:17(10):1369-73
[PubMed PMID: 23740451]
Level 3 (low-level) evidence
[81]
Lotery A, Sivaprasad S, O'Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U, Peto T, Rogers CA, Reeves BC, VICI trial investigators. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2020 Jan 25:395(10220):294-303. doi: 10.1016/S0140-6736(19)32981-2. Epub
[PubMed PMID: 31982075]
Level 1 (high-level) evidence
[82]
Steinle NC, Gupta N, Yuan A, Singh RP. Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy. The British journal of ophthalmology. 2012 Jan:96(1):10-3. doi: 10.1136/bjophthalmol-2011-300183. Epub 2011 Nov 3
[PubMed PMID: 22053102]
[83]
Ravage ZB, Packo KH, Creticos CM, Merrill PT. Chronic central serous chorioretinopathy responsive to rifampin. Retinal cases & brief reports. 2012 Winter:6(1):129-32. doi: 10.1097/ICB.0b013e3182235561. Epub
[PubMed PMID: 25390732]
Level 3 (low-level) evidence
[84]
Tatham A, Macfarlane A. The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2006 Apr:22(2):145-9
[PubMed PMID: 16722801]
[85]
Avci R, Deutman AF. [Treatment of central serous choroidopathy with the beta receptor blocker metoprolol (preliminary results)]. Klinische Monatsblatter fur Augenheilkunde. 1993 Mar:202(3):199-205
[PubMed PMID: 8510413]
[86]
Tripathy K, Chawla R, Vekaria L, Sharma YR. Sub-internal Limiting Membrane Cavity Following Valsalva Retinopathy Resembling Central Serous Chorioretinopathy. Journal of ophthalmic & vision research. 2018 Jan-Mar:13(1):83-84. doi: 10.4103/jovr.jovr_192_16. Epub
[PubMed PMID: 29403598]
[87]
Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy. The British journal of ophthalmology. 1984 Nov:68(11):815-20
[PubMed PMID: 6541945]